Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
about
Clinical Benefits of Stem Cells for Chronic Symptomatic Systolic Heart Failure A Systematic Review of the Existing Data and Ongoing Trials.Effects of Transendocardial Stem Cell Injection on Ventricular Proarrhythmia in Patients with Ischemic Cardiomyopathy: Results from the POSEIDON and TAC-HFT TrialsRandomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.Where Does Inflammation Fit?Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure.Publication trends in cachexia and sarcopenia in elderly heart failure patients.Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics.Macrophage-based therapeutic strategies in regenerative medicine.Stem cell therapy for the systemic right ventricle.Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia.University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion).Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells.Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction.Global position paper on cardiovascular regenerative medicineAdjuvant role of macrophages in stem cell-induced cardiac repair in rats
P2860
Q31110980-D8ABDA2C-4036-4768-9DD8-2E33E3231483Q33722076-8B485ADD-5B37-412D-AC27-FBD1240FDF79Q37624397-9A9E24BE-C8EB-4367-AD70-2C0C873B1034Q37738591-42441B8D-AB16-4F21-B171-685FFCDD7603Q38639570-FF35A291-9338-467C-8710-32DB83E2E09AQ38653210-48A12F98-89FE-4CBC-BA3F-14184942C48BQ38801590-19C74D84-798E-4F4A-8D99-69AEAAC1BC0BQ38885298-0DF7BD01-990A-475E-8DA8-8037DC0D5241Q39019268-E049486B-6B67-4028-8DE8-BA36334507C9Q39149000-D86F6820-A75D-4E9E-88AB-83D160E2E880Q39319066-8710FAF9-AFD2-47F2-9871-51B93F61C125Q41997705-7634A770-3208-41F6-B9EB-8FFE0134A6CAQ42378809-62B10FCA-AAB4-472D-9E88-688140940E9AQ47304892-63129A00-A1AA-42F5-99F3-EAF9DD961195Q47639049-36DE2A5D-F9B2-4F17-A0F3-0E3D284B3000Q47744623-38B4E036-FEE0-4F98-BD4F-1C2259B8EFDCQ56985687-2E74957E-B67F-4F64-8287-B9FBBBC4EB17Q58610198-1107AA83-B400-4E9E-8751-17CCBF56F97B
P2860
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@en
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@nl
type
label
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@en
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@nl
prefLabel
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@en
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@nl
P2093
P1433
P1476
Ixmyelocel-T for patients with ...... randomised double-blind trial.
@en
P2093
Akshay S Desai
Ann E Remmers
Anthony DeMaria
Arshed A Quyyumi
Catalin Toma
David Recker
Gary L Schaer
James Goodrich
R David Anderson
P304
P356
10.1016/S0140-6736(16)30137-4
P407
P50
P577
2016-04-05T00:00:00Z